Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Haoran Xia(Tongji University), Gening Jiang(Tongji University), Wenxin He(Tongji University), Xiaomiao Zhang(Shanghai Jiao Tong University), Hezhong Chen(Tongji University), Deping Zhao(Second Military Medical University), Dongliang Bian(Tongji University), Nan Song(Liaoning University of Traditional Chinese Medicine), Xinsheng Zhu(Tongji University), Liang Duan(Dalian Medical University), Huibiao Zhang(Tongji University), Zheng Ruan(Shanghai Jiao Tong University), Jian Chen(Tongji University), Peng Zhang(Second Affiliated Hospital of Xi'an Jiaotong University), Xiaogang Liu(Tongji University), Han Zhang(Tongji University), Jing Zhang(Shanghai Jiao Tong University), Haiping Zhang(Tongji University), Lele Zhang(Tongji University), Yongxin Zhou(Tongji University), Shiliang Xie(Tongji University), Liangdong Sun(Tongji University), Huansha Yu(Tongji University), Jie Yang(Tongji University), Fenghuan Sun(Tongji University), Dongfang Tang(Huadong Hospital), Yuming Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Qinchuan Li(Shanghai East Hospital), Guohan Chen(Shanghai East Hospital)
Signal Transduction and Targeted Therapy
June 13, 2024
Cited by 30


Related Papers